Fingolimod (FTY720), S1P receptor modulator

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The S1P1 receptor also known as EDG1 is a G-protein-coupled receptor that plays a significant role in the sphingosine-1-phosphate (S1P) signaling pathway. With a molecular mass of approximately 43 kDa S1P1 is expressed in various tissues such as vascular endothelial cells immune cells and cardiac cells. The protein mediates the effects of sphingosine-1-phosphate a bioactive lipid that participates in various physiological processes.

Biological function summary

S1P1 is involved in the regulation of immune cell trafficking and vascular stability. As a part of a receptor complex it activates intracellular signaling cascades that influence cell migration and vascular maturation. By binding to S1P S1P1 controls the egress of lymphocytes from lymphoid tissues indicating its important role in immune surveillance and response.

Pathways

S1P1 serves as an important component in the S1P signaling pathway and the phosphoinositide 3-kinase (PI3K) pathway. In the S1P pathway it regulates endothelial cell barrier function and vascular maturation. In the PI3K pathway S1P1 influences cell survival and migration which relates it to protein kinases like Akt and other signaling molecules that further modify cellular responses.

S1P1 is implicated in multiple sclerosis (MS) and cancer progression. In MS S1P1 modulation affects lymphocyte trafficking which is the mechanism behind the action of fingolimod (FTY720) a therapeutic agent for the disease. S1P1 also connects to VEGF and other angiogenic factors in cancer where it influences tumor angiogenesis and metastasis. Understanding these connections highlights the potential for targeting S1P1 in therapeutic strategies for these conditions.